Invasive candidiasis is a serious problem in intensive care unit (ICU) patients. From a retrospective matched case-control study in the United Kingdom between 2003 and 2007, the attributable mortality of candidiasis in ICU patients was estimated to be 28.3% (1).

One of the risk factors for mortality of patients with candidemia is inadequate antifungal therapy (2–4). For fluconazole, apart from delayed start of treatment (5), the area under the concentration-time curve (AUC) divided by the MIC has an impact on the mortality of patients with invasive Candida infections (6). Echinocandins are relatively new antifungal agents that are valuable for the treatment of patients with invasive candidiasis (7). Anidulafungin compared favorably with fluconazole in critically ill patients, particularly if given as empirical therapy (8). In a neutropenic murine disseminated candidiasis model, the AUC/MIC ratio of anidulafungin was a good predictor of efficacy (9, 10).

Anidulafungin has predictable pharmacokinetics in healthy volunteers; exposure is dose dependent and there is a low interindividual variability (11). In patients with fungal disease, anidulafungin clearance appeared to be approximately 30% higher in patients with invasive candidiasis than in patients with esophageal candidiasis. Patients with invasive candidiasis were more severely ill than patients with esophageal candidiasis (12). For caspofungin, the trough concentrations were more variable and correlated with albumin concentrations in surgical intensive care patients (13). However, at this time, there are limited data available on the pharmacokinetics of anidulafungin in critically ill patients (14).

The objective of this study was to determine the anidulafungin concentrations and exposure in critically ill patients and explore a possible correlation with disease severity or plasma protein levels.
tained at day 3 (± 1 day) after the start of anidulafungin. Blood samples were taken just before administering anidulafungin and at 1.5, 2, 3, 4, 6, 8, 12, and 24 h after the start of the infusion. In addition, every 3 days during treatment, blood samples for anidulafungin trough concentrations were collected during ICU admission.

For each patient included, data were collected from the medical chart, including demographic data, medical history, and laboratory parameters. Total body water volumes were estimated using the method of Watson (15).

Predictive scoring systems were used to assess the disease severity. Disease severity scores have been developed to measure the disease severity and overall prognosis of patients, not to explain variability in pharmacokinetics, although they were successfully used earlier for this purpose (16–19). The scores that were calculated were the acute physiology and chronic health evaluation II (APACHE II) (20), logistic organ dysfunction system (LODS) (21), multiple organ dysfunction score (MODS) (22), organ dysfunctions and/or infection (ODIN) (23), simplified acute physiology score (SAPS II) (24), SAPS 3 (25), and sepsis-related organ failure assessment (SOFA) (26). All these different scores capture different aspects of disease severity; we calculated all of these scores to search for an appropriate disease severity score to correlate with anidulafungin exposure. The disease severity was assessed on the day that the concentration-time curve was obtained. On the same day, albumin and total protein concentrations in plasma were measured. Mortality was assessed at day 28 of treatment.

Anidulafungin pharmacokinetics. Blood samples (4 ml) were drawn into Vacutainer tubes (Becton, Dickinson, Franklin Lakes, NJ). Plasma was separated and frozen at −80°C until it was processed. All samples were analyzed with a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method that was validated according to the guidelines for bioanalytical method validation of the FDA (27). Sample preparation consisted of protein precipitation using aculeacin A as the internal standard. The method is accurate (bias ranging from −3.0 to 1.9%) and precise (within-run and between-run coefficients of variation of 2.2 to 7.7% and 1.6 to 9.0%, respectively). All calibration curves were linear over a range of 0.5 to 10.0 mg/liter for anidulafungin.

The AUC from 0 to 24 h (AUC₀–₂₄) was calculated using the log-linear trapezoidal rule with KINFIT (MWPharm 3.60; Mediware, the Netherlands) (28). The clearance (CL) was estimated by dividing the dose administered by the AUC₀–₂₄.

Microbiology. MIC values were determined with the Etest (bioMérieux, Marcy l’Etoile, France). Etest assays were performed using RPMI glucose agar and inoculum density adjustment with a 0.5 McFarland standard. The plates were incubated at 35°C and were read after 24 h. If no growth was detected, the plates were incubated for another 24 h. The drug concentration shown on the Etest strip at the outer border of the elliptical inhibition halo was recorded as the MIC.

Pharmacokinetics/pharmacodynamics. For the assessment of sufficient exposure, the calculated anidulafungin AUC in proportion to the MIC (AUC₀–₂₄/MIC) for each patient was compared with a target value based on European Committee on Antimicrobial Susceptibility Testing (EUCAST) data (29). Exposure for the general patient population of 110 mg · h/liter (11) is accepted as sufficient to treat infections with susceptible Candida species (29). A Candida species was considered susceptible if its MIC was not higher than the EUCAST clinical breakpoint. The free fraction of anidulafungin is assumed to be 1% (11). Therefore, the target value for Candida albicans [(110 mg · h/liter · 1%)/0.03 mg/liter] was 36.7. For Candida glabrata, the target value [(110 mg · h/liter · 1%)/0.06 mg/liter] was 18.3.

Statistics. Based on a large variation in disease severity and the consequent expectation of a large variation in pharmacokinetics, a sample size of 18 patients is needed to detect a clinically relevant correlation of 60% with 80% power and significance level of α = 0.05 (two-sided). We planned to recruit 20 patients to cover a dropout rate of 10%.

The Mann-Whitney U test was used to assess whether the continuous data from two groups was significantly different. Correlations were determined with the Spearman correlation coefficient (rₛ) in SPSS version 20 (IBM, Armonk, NY).

Multiple linear regression analysis was performed using a backward elimination strategy, keeping variables with P values of <0.1 in the model. The variables that were included in the multiple linear regression analysis were gender (11), age (11), total body water (11), albumin (13), total bilirubin (30, 31), and the disease severity score with the lowest P value for the correlation.

RESULTS
Twenty patients were included; nine were female. Most patients were admitted after abdominal surgery with complications or severe abdominal infections. An overview of patient characteristics is shown in Table 1.

At day 28 after the start of treatment with anidulafungin, five of the patients were deceased. These patients died while on treatment with anidulafungin, at 4, 6, 7, 15, and 16 days after the start of treatment. All five patients died after withholding and withdrawing of therapy because of progressive multiple organ failure and lack of treatment options for the underlying disease. All patients suffered from infections when they died, but because no autopsies were performed, it remains uncertain whether they died because of infection or with infection and whether the Candida infection was still present.

Anidulafungin pharmacokinetics. The mean concentration-time curve of anidulafungin with standard deviations (SD) is presented in Fig. 1. The mean (± SD) AUC₀–₂₄, maximum concentration of drug in plasma (Cmax), and minimum concentration of drug in plasma (Cmin) were 69.8 ± 24.1 mg · h/liter, 4.7 ± 1.4 mg/liter, and 2.2 ± 0.8 mg/liter, respectively. Both the anidulafungin Cmax and Cmin showed a significant correlation with the anidulafungin exposure (Cmax, rₛ = 0.854, P < 0.001; Cmin, rₛ = 0.884, P < 0.001). The mean (± SD) estimated clearance was 1.6 ± 0.6 liters/h.

The anidulafungin trough concentrations ranged from 1.0 mg/liter to 4.7 mg/liter during treatment.

On the first day of treatment with anidulafungin, the mean (± SD) anidulafungin plasma concentration at the end of the in-
fusion was $4.9 \pm 1.4 \text{ mg/liter}$. Twelve hours after start of the infusion, the mean anidulafungin concentration was $2.3 \pm 0.6 \text{ mg/liter}$. For logistical reasons, it was not possible to obtain samples from four patients on the first day of treatment.

**Microbiology.** Blood cultures for *Candida* were positive in 7 patients, and for 17 patients, intra-abdominal fluid cultures were positive. In 13 patients, *C. albicans* was cultured, and in 11 patients, *C. glabrata*. No other *Candida* species were recovered. The MIC values for *C. albicans* ranged from $0.002$ to $0.008 \text{ mg/liter}$, whereas the MIC values for *C. glabrata* were also lower than the EUCAST MIC breakpoint of $0.03 \text{ mg/liter}$. For logistical reasons, it was not possible to obtain samples from four patients on the first day of treatment.

The plasma protein concentrations were low in these patients. As expected, all 20 patients had albumin concentrations below the lower limit of normal (35 g/liter). The mean albumin concentration was $19 \text{ g/liter}$ (range, 14 to 31 g/liter). The total protein concentration of most patients was also below the lower limit of normal (35 g/liter). The mean albumin concentration was $62 \text{ g/liter}$, with a mean of $46 \text{ g/liter}$. Neither albumin nor total protein concentrations could be established ($rs = 0.092, P = 0.700$).

**Pharmacokinetics/pharmacodynamics.** The mean ($\pm SD$) $fAUC_{0-24}/\text{MIC}$ ratio was $229 \pm 105$ for *C. albicans* and $118 \pm 101$ for *C. glabrata* and appeared to be above the target value for all patients based on EUCAST data. Figure 2 shows the AUC$_{0-24}$ that was determined versus the MIC of the *Candida* species isolated.

**Evaluation of possible variables of anidulafungin exposure.** Table 2 provides the median disease severity scores and data regarding a possible correlation with the anidulafungin exposure, reflected by the AUC$_{0-24}$. None of the disease severity scores showed a significant correlation with the anidulafungin exposure.

The plasma protein concentrations were low in these patients. As expected, all 20 patients had albumin concentrations below the lower limit of normal (35 g/liter). The mean albumin concentration was $19 \text{ g/liter}$ (range, 14 to 31 g/liter). The total protein concentration of most patients was also below the lower limit of normal (60 g/liter). Total protein concentrations ranged from 29 to 62 g/liter, with a mean of $46 \text{ g/liter}$. Neither albumin nor total protein concentration showed a significant correlation with the anidulafungin exposure (AUC$_{0-24}$) ($r_s = 0.099, P = 0.677$, and $r_s = 0.092, P = 0.700$).

No significant correlation was observed between the anidulafungin exposure and the body weight of patients ($r_s = 0.282, P = 0.229$). The correlation with total body water did not reach statistical significance ($r_s = 0.427, P = 0.061$). A possible correlation between anidulafungin exposure and total bilirubin concentrations also could not be established ($r_s = 0.312, P = 0.181$). In the multiple linear regression analysis, the model is $0.345$.

The deceased patients did not seem to have a different anidulafungin exposure than the surviving patients; the respective median exposures were $68.9 \text{ mg} \cdot \text{h/liter}$ (range, 64.2 to 89.5 mg · h/liter) and $60.8 \text{ mg} \cdot \text{h/liter}$ (range, 32.4 to 124.4 mg · h/liter).

**DISCUSSION**

We found low exposure to anidulafungin in our critically ill patients. Although the exposure was low, the MICs of the *Candida* species isolates were also low, and therefore, none of our patients received inadequate antifungal treatment. No correlation was observed between anidulafungin exposure and disease severity or plasma protein concentration in this group of critically ill patients.

**TABLE 3** Multiple linear regression analysis for anidulafungin exposure

<table>
<thead>
<tr>
<th>Variable</th>
<th>$\beta$ (95% CI)*</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total body water</td>
<td>$-2.566 (-4.192$ to $-0.941)$</td>
<td>0.004</td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>$0.232 (0.036$ to $0.428)$</td>
<td>0.023</td>
</tr>
</tbody>
</table>

* $\beta$, regression coefficient of the population; 95% CI, 95% confidence interval.
An explanation for the lack of correlation could be that anidulafugin exposure is influenced slightly by several factors at the same time, making it difficult to correlate anidulafugin exposure with disease severity, plasma protein concentrations, or other contributing factors. Total body water, expected to be similar to the volume of distribution of anidulafugin (11), was also not significantly correlated to anidulafugin exposure. Based on studies with micafugin, which showed a reduced elimination clearance in the case of cholestatic hyperbilirubinemia (31) and a correlation of micafugin concentrations with total bilirubin (30), we explored a possible correlation between bilirubin concentrations and anidulafugin exposure. The expectation was that in patients with high bilirubin concentrations, the excretion of bilirubin and anidulafugin into bile would be decreased. No correlation could be established. As no correlation was observed between anidulafugin exposure and the individual contributing factors, a multiple linear regression analysis was performed. The multiple linear regression analysis provided a significant correlation between anidulafugin exposure and total body water and bilirubin concentrations. No significant correlations were observed between anidulafugin exposure and disease severity or plasma protein concentrations.

The group of patients is on the one hand a limitation and on the other hand a strength of this study. The limitation is that our group of patients was relatively homogeneous with respect to their critical illness and plasma protein concentrations. Possibly, this could be another explanation for the lack of correlation between anidulafugin exposure and disease severity or plasma protein concentrations. The strength of this group is that these are the critically ill patients that are in need of treatment with an echinocandin.

The low anidulafugin exposure in our group of patients compared to the exposure in the general patient population was expected based on previously published data (12), as anidulafugin clearance appeared to be approximately 30% higher in the more severely ill patients with invasive candidiasis than in patients with esophageal candidiasis. The anidulafugin exposure also appeared to be significantly lower ($P = 0.045$, Mann-Whitney $U$ test) than was evidenced by earlier data from other intensive care patients, i.e., 69.8 ± 24.1 mg-h/liter versus 92.7 ± 38.0 mg-h/liter (14). From the data available for both groups, it appears that our patients were significantly older ($P = 0.004$), heavier ($P = 0.001$), and taller ($P = 0.032$) and had a higher total body water volume ($P = 0.007$). Further analysis is required to determine other factors causing the apparent difference.

The observed lower exposure appeared to be not clinically relevant for our patients. To assess the clinical relevance of the observed lower anidulafugin exposure, the $\text{fAUC}_{0-24}/\text{MIC}$ ratio was used based on the listed sample size and the complex pathology of critically ill patients. This could be advocated because the AUC/MIC ratio appeared to be a good predictor of anidulafugin efficacy (9, 10). We did not use the target values from these studies (9, 10) because the MICs used were measured with the CLSI method, whereas our MICs were determined with an Etest. MICs determined with an Etest are usually lower than those determined with the CLSI method (32) and were used in determining the EUCAST breakpoints; therefore, we used target values based on EUCAST data. The observed lower exposure combined with the low MICs of the Candida species that were isolated resulted in favorable $\text{fAUC}_{0-24}/\text{MIC}$ ratios in our patients.

Further research is necessary on factors that contribute to the variability of anidulafugin exposure, because total body water and bilirubin only partly explain the variability in anidulafugin exposure. This is necessary in order to anticipate a lower exposure in patients before starting treatment with anidulafugin, as the MIC of the pathogen is usually not available at that moment. Besides, validation of target values for the $\text{fAUC}_{0-24}/\text{MIC}$ ratio in clinical practice is needed. Investigation of limited sampling strategies for anidulafugin could be useful for future research and for specific clinical situations.

No correlation could be established between anidulafugin exposure and disease severity or plasma protein concentrations in this group of critically ill patients. In this population, we observed a lower anidulafugin exposure than in the general patient population. In patients infected with a susceptible Candida albicans or glabrata strain with a MIC well below the breakpoint, no problems are to be expected in the case of a lower exposure. However, in patients with less-susceptible Candida albicans or glabrata strains, a lower exposure can be a problem. If the MIC is high or unknown, we recommend considering determining the anidulafugin exposure to ensure that the exposure is adequate.

ACKNOWLEDGMENTS
We thank the staff of the Clinical and Hospital Pharmacy, Medical Microbiology, and Critical Care Departments in our hospital for their contribution to this study.

This investigator-initiated study was financially supported by Pfizer.

REFERENCES


8. Kett DH, Shore AF, Rebolli AG, Reisman AL, Biswas P, Schlamm HT. 2011. Anidulafugin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the